Drugs / Allergen Immunotherapy Extract
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03360071 | Dec 2016 → Jun 2018 | allergic rhinitis | Johns Hopkins University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07694947 | Jan → Jul 2023 | allergic asthma | Mansoura University Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05786638 Comparator | Oct 2021 → Oct 2022 | — | Mansoura University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allergen Immunotherapy Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360071 ↗ |
| Modality | Vaccine | “subcutaneous immunotherapy (SCIT) vaccines” NCT05786638 ↗ |
| Route | Subcutaneous | “Allergen Immunotherapy treatment mixture to be delivered subcutaneously” NCT03360071 ↗ |